Epigenomics AG

  • WKN: A11QW5
  • ISIN: DE000A11QW50
  • Land: Deutschland

Nachricht vom 15.07.2019 | 15:49

Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9

Epigenomics AG / Key word(s): Patent/Legal Matter
Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9

15-Jul-2019 / 15:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9

Berlin, 15 July 2019 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announced today that the Reexamination and Invalidation Department of the Patent office, China National Intellectual Property Administration (CNIPA) has, today, deemed Epigenomics' Septin9 patent in China only partially valid. It has not been recognized for the detection of hepatocellular cancer. For the detection of colorectal cancer it has been recognized to the extent the detection is based on biological samples consisting of cell lines, histological slides, biopsies, paraffin-embedded tissue, stool, colonic effluent and combinations thereof, but not for detections based on body fluids (urine, blood plasma, blood serum, whole blood, isolated blood cells, cells isolated from the blood and combinations thereof). The decision is not yet legally effective. Epigenomics will appeal.

This decision of the CNIPA has no impact on revenue estimates for 2019 as Epigenomics did not include any Chinese licensing revenue in 2019 guidance. The decision by the CNIPA in China has no impact on Epigenomics' Septin9 patents in other parts of the world.


Contact:
Company
Epigenomics AG, Geneststraße 5, 10829 Berlin, Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com


Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 


15-Jul-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UmweltBank AG mit deutlichem Kurspotenzial

Die UmweltBank AG, die als einzige Bank Deutschlands den Umweltgedanken in der Satzung verankert hat, präsentierte in den letzten Jahren beeindruckende Wachstumszahlen. Sowohl die Kundeneinlagen als auch das Kreditbuch legten um durchschnittlich gut 6,3 % zu. Seit seiner Gründung hat das Kreditinstitut stets positive Ergebnisse erzielt, zuletzt im Geschäftsjahr 2018 einen Jahresüberschuss in Höhe von 25,3 Mio. €. Wir haben ein Kursziel von 14,30 € je Aktie ermittelt, was deutlich oberhalb des aktuellen Kursniveaus liegt. Die Dividendenrendite liegt bei fast 3,0 %.

Aktuelle Research-Studie

Aroundtown SA

Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): BUY

27. Januar 2020